Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 5—May 2014
Research

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Suzanne M. MarksComments to Author , Jennifer Flood, Barbara Seaworth, Yael Hirsch-Moverman, Lori Armstrong, Sundari Mase, Katya Salcedo, Peter Oh, Edward A. Graviss, Paul W. Colson, Lisa Armitige, Manuel Revuelta, Kathryn Sheeran, and the TB Epidemiologic Studies Consortium
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Marks, L. Armstrong, S. Mase, TB Epidemiologic Studies Consortium); California Department of Public Health, Richmond, California, USA (J. Flood, K. Salcedo, P. Oh); Texas Department of State Health Services, Tyler, Texas, USA (B. Seaworth, L. Armitige, K. Sheeran); University of Texas Health Science Center, Tyler (B. Seaworth, L. Armitige, K. Sheeran); ICAP/Columbia University, New York, New York, USA (Y. Hirsch-Moverman, P.W. Colson, M. Revuelta); Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss)

Main Article

Table 2

Socioeconomic characteristics of study participants and all patients with MDR and/or XDR TB, United States, 2005–2007*

Characteristic Study participants, no. (%), n = 135 All US MDR TB patients, no. (%), n = 370
Unemployed† 38 (28) 187 (51)
Homeless 9 (7) 20 (5)
Correctional institution resident 6 (4) 7 (2)
Long-term care facility resident
 4 (3)
 6 (2)
Injection drug use 5 (4) 8 (2)
Noninjection drug use† 12 (9) 15 (4)
Excess alcohol use 15 (11) 31 (8)
Smoker
 31 (23)
Pregnant at treatment initiation 6 (4)
Private health insurance, % of 112 known 24 (21)
Public health insurance, % of 112 known 49 (44)
Jail/prison health coverage, % of 112 known 2 (2)
Other health insurance, % of 112 known 5 (4)
No health insurance, % of 112 known
 32 (29)
HIV+ 14 (10) 29 (8)
Receiving HAART 9 (64)
Receiving ART 1 (7)
Receiving neither HAART nor ART 3 (21)
Receipt of ART not documented
 1 (7)
Not HIV infected 102 (76) 205 (55)
HIV status unknown
 19 (14)
 136 (37)
Diabetes, % of 121 known 24 (20)
ESRD, % of 121 known 3 (2)
Prolonged corticosteroid therapy, % of 121 known 2 (2)
Other immunosuppressive therapy, % of 121 known 2 (2)
Cancer, % of 121 known 3 (2)
Hematologic diseases, % of 121 known 2 (2)

*Study patients were from California, New York City, and Texas. MDR, multidrug resistant; XDR, extensively drug resistant; TB, tuberculosis; HIV+, HIV infected; HAART, highly active antiretroviral therapy; ART, antiretroviral therapy; ESRD, end-stage renal disease. Blank cells indicate data not available.
†Statistically significant differences between percentages of study patients and all US MDR TB patients at p<0.05.

Main Article

Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external